Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Genomic landscape of treatment refractory metastatic colorectal cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Drop in cancer diagnosis during the COVID-19 pandemic in Denmark: assessment of impact during 2020

    Research output: Contribution to journalLetterResearchpeer-review

  2. Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders

    Research output: Contribution to journalLetterResearchpeer-review

  3. The impact of tobacco smoking on survival of patients with oral squamous cell carcinoma: a population-based retrospective study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Substantial Lymphovascular Space Invasion Is an Adverse Prognostic Factor in High-risk Endometrial Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Identification of Stably Expressed Reference microRNAs in Epithelial Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Metastatic colorectal cancer (mCRC) is a complex and heterogeneous disease with few standard and targeted treatment options. Next-generation sequencing of tumor tissue was performed to identify cancer driver mutations to discover possible personalized treatment options, as targeted treatment possibilities are limited for this patient population. Results of genomic sequencing in patients with treatment-refractory mCRC are described in this retrospective analysis.

MATERIAL AND METHODS: Clinico-pathological characteristics and genomic sequence results of consecutive patients with refractory mCRC, referred to the Experimental Cancer Therapy Unit (ECTU) at Department of Oncology, Herlev & Gentofte Hospital in the period from 1 October 2015 to 14 December 2018 were reviewed in this retrospective analysis. Tumor tissue from the patients was analyzed by next-generation sequencing using the Oncomine Comprehensive primer panel to detect actionable variants of cancer driver mutations and microsatellite instability status. From August 2018 tumor mutational burden was also analyzed.

RESULTS: A total of 80 patients with treatment-refractory mCRC and in a fairly good performance were referred to the ECTU during this period. Genomic sequencing of tumor tissue was performed for all 80 patients and a cancer driver mutation was identified in 90% (n = 72) of the patients. A total of 31.3% (n = 25) of the patients received therapy either as targetable therapy outside an available trial (n = 2), FDA approved therapy (n = 2), or treatment in phase 1 or 2 trials, independent of the genomic signature 26.3% (n = 21).

CONCLUSION: Most mCRC patients refractory to standard anti-neoplastic therapies, presented with a cancer driver mutation, however, only a few of these mutations gave rise to matched therapies as only 2.5% of the patients from this period received targeted therapy.

Original languageEnglish
JournalActa Oncologica
Volume60
Issue number12
Pages (from-to)1621-1628
Number of pages8
ISSN0284-186X
DOIs
Publication statusPublished - Dec 2021

    Research areas

  • Biomarkers, Tumor, Colonic Neoplasms, Colorectal Neoplasms/drug therapy, Genomics, High-Throughput Nucleotide Sequencing, Humans, Mutation, Retrospective Studies

ID: 70952436